The Career of Patriots Wide Receiver Julian Edelman

Friday, August 25, 2017

The Career of Patriots Wide Receiver Julian Edelman

A former Albert Einstein College of Medicine Pfizer Scholar in Urology, Erol Onel has over two decades of experience in clinical research and education. When not providing scientific leadership as vice president of Heron Therapeutics, Erol Onel enjoys following his favorite National Football League team, the New England Patriots.

Last year, the Patriots won their fifth Super Bowl since 2001, and for the second time in the past four years, their leading receiver was Julian Edelman. A native of Redwood City, California, Edelman recorded a career-high 1,106 receiving yards on 98 receptions last year. He scored three touchdowns and rushed for 57 yards on 12 attempts. Named the AFC Offensive Player of the Week in Week 17 after accumulating 151 receiving yards in a 35-14 win over the Miami Dolphins, he caught 21 passes for 342 yards in three playoff games.

Throughout his eight-year career, Edelman has accumulated 24 touchdowns and 4,540 receiving yards. He was selected in the seventh round of the 2009 NFL Draft out of Kent State, where he played quarterback and threw for 30 touchdowns and 4,997 yards in three seasons. In his final season of college football, he displayed his versatility by rushing the ball for 1,370 yards and scoring 13 touchdowns.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

About Erol Onel

A physician in New Jersey focused on pharmaceutical development, Erol Onel, MD, most recently served Pacira Pharmaceuticals, Inc., as vice president of clinical research and medical information. In these roles, Dr. Erol Onel’s responsibilities included overseeing studies presented to the US Food and Drug Administration and engaging with Pacira’s regulatory department to ensure the completion and transmission of regulatory documentation. Among his accomplishments at Pacira, he guided the launch and approval of the firm’s major product, a non-opioid pain medication.

Over the course of his career, Dr. Onel has led held leadership roles in all areas of clinical development. With particular experience in male fertility, he played an integral role in the development of degarelix (Firmagon), a drug used in the treatment of prostate cancer.

Dr. Erol Onel earned his doctor of medicine at Yeshiva University’s Albert Einstein College of Medicine and completed a residency in urology at the University of Connecticut Health Center. Subsequently, he fulfilled the obligations of a research fellowship in andrology and sexual dysfunction at the University of Illinois at Chicago.